Niraparib metabolite M1 is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase ( PARP ) inhibitor.
In Vitro
Niraparib metabolite M1 has the validation in plasma and urine for the support of clinical studies such as the mass balance study and the absolute bioavailability study. MCE has not independently confirmed the accuracy of these methods. They are for reference only.